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Alternative therapeutic options in patients with advanced gastrointestinal
cancer
GC Wishart and TG Cooke
University Department ofSurgery, Royal Infirmary, Glasgow G31 2ER, UK.
The prognosis of patients with advanced gastrointestinal
cancer is extremely poor. Current chemotherapeutic regimens
in gastric and colorectal cancer have low response rates and
are often highly toxic. As a result there has been much
interest in novel forms of therapy in an attempt to identify
new therapeutic options which will be more effective in the
treatment of these patients. Several different classes of drugs
have received increasing attention during the last few years
and merit further investigation.
In this issue ofthejournal Cascinu et al. present the results
of a randomised trial in 107 patients with advanced gastro-
intestinal cancer refractory to chemotherapy comparing treat-
ment with the somatostatin analogue octreotide with best
supportive care only. Stratification for performance status
and the primary tumour was carried out prior to randomisa-
tion. Octreotide was administered by subcutaneous injection
(200 g, three times daily, 5 days per week) and was con-
tinued until there was disease progression, unacceptable tox-
icity or patient refusal with a median treatment duration of
12 weeks (range 6-32 weeks). Treatment with octreotide
conferred a significant survival advantage with a median
survival of 20 weeks in the active arm compared with 11
weeks in the control arm (P<0.0001). A previous trial which
randomised 260 chemotherapy-naive patients in a similar way
to a lower dose of subcutaneous octreotide (150Mg, three
times daily) had failed to demonstrate any difference in either
survival or time to progression in the treatment arm (Krook
et al., 1993). The difference in outcome may be due to the
different cohort of patients, with no exposure to
chemotherapy in the latter group, or to the different dose
intensity of octreotide. It is of interest that the significant
survival advantage in the study by Cascinu et al. occurs in
the absence of any objective response to octreotide consistent
with two previous non-randomised trials which reported
stabihsation of disease only (Klijn et al., 1990; Smith et al.,
1992). Furthermore, the latter study demonstrated that sur-
vival was markedly prolonged in those patients with pretreat-
ment elevated gastrin levels, suggesting that this therapy
could perhaps be further improved by targeting specific
tumour subgroups. In a similar way, other hormonal
manipulation could also be targeted to specific tumours
depending on the receptor status of individual growth
factors/hormones. The exact mechanism by which somatos-
tatin exerts its anti-tumour effect is not known, but several
different theories have been described.
Somatostatin is a naturally occurring antitrophic hormone
which has many diverse functions throughout the body. It
inhibits the release of gastrin and growth hormone and
interacts with the secretion ofepidermal growth factor (EGF)
and insulin-like growth factor I (IGF-I) (Schally, 1988). The
short plama half-life of somatostatin detracted from its
clinical application, but several analogues have now been
synthesised which have a longer duration of action while
retaining the anti-tumour activity. These analogues bind to
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specific somatostatin receptors that are coupled to a variety
of signal transduction pathways including tyrosine phos-
phatase. Stimulation of tyrosine phosphatase in receptor sub-
types SSTRI and SSTR2 has recently been implicated in the
inhibition of cell proliferation in vitro (Buscail et al., 1994).
Low-affinity, high-capacity binding sites can be identified in
both normal and malignant gastrointestinal mucosa (Miller
et al., 1992) but there appears to be no correlation between
receptor status and either the differentiation or grade of the
primary tumour in colorectal cancer (Radulovic et al., 1992;
Iftikhar et al., 1992). A more detailed study has recently
shown increased detection of the SSTR2 receptor subtype in
the smooth muscle layer of peritumoral veins surrounding
human colonic cancer specimens (Reubi et al., 1994). Since
these receptors are sparse in normal gastrointestinal mucosa
it is proposed that increased expression of the SSTR2 sub-
type may be tumour specific and play a role in tumour-host
interactions.
There is now an abundance of experimental data to sup-
port the anti-mitogenic role of somatostatin both in vitro and
in vivo. Somatostatin analogues inhibit the basal and gastrin-
stimulated growth of several human colonic cancer cell lines
in vitro and cause significant growth delay in human colon
cancer xenograft studies (Dy et al., 1992; Alonso et al., 1992).
Furthermore, the growth and development of hepatic metas-
tases can be reduced by treatment with the somatostatin
analogues SMS 201-995 (Nott et al., 1989) and RC-160 (Qin
et al., 1992), suggesting a more specific potential role in the
treatment of hepatic metastases of colorectal origin.
Somatostatin, however, is only one of a number ofhormones
which are known to interact with both normal and neoplastic
gstrointestinal epithelial cells.
There is now increasing evidence that tumours arising from
the gastrointestinal tract may be partly hormone dependent
and that hormonal manipulation may have a role to play in
the treatment of these tumours. The proliferation of normal
gastrointestinal mucosa is controlled by a number of hor-
mones and growth factors. Gastrin, a polypeptide hormone
which is trophic for normal gastrointestinal tract epithelial
cells (Johnson, 1977), has been shown to promote the growth
of human gastric and colon cancer cells in vitro (Watson et
al., 1988). Furthermore, gastrin stimulates the in vivo growth
of 50% of gastric and colorectal carcinoma xenografts (Bald-
win and Whitehead, 1994). Despite this experimental
evidence supporting the role ofgastrin as a mitogen in gastric
tumours in vitro and in vivo, there appears to be no evidence
that it plays a role in the development of gastric adenocar-
cinoma. The prolonged hypergastrinaema associated with
type A atrophic gastritis does not increase the incidence of
either gastric or colorectal adenocarcinoma despite the 3-fold
increase in gastric cancer in patients with pernicious anaemia
(Brinton et al., 1989). In contrast, the hypergastrinaemia
associated with either pernicious anaemia or type A atrophic
gastritis does increase the risk ofdeveloping gastric endocrine
(carcinoid) tumours. The elevated basal serum gastnn level in
patients with colon cancer (Sobhani et al., 1992) may
therefore be a tumour product rather than an aetiological
factor, in keeping with the hypothesis that gastrin and otherMlsrnative thepeutic options in paents with advanced gasroinestnl cancer
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gut hormones may act as autocrine growth factors for gastro-
intestinal cancer.
Several studies have shown that EGF transforming growth
factor a (TGF-a) and IGF-I may be implicated in the autoc-
rine control of gastric and colorectal tumour cell growth. In
a series of human gastric and colorectal cancer cell lines in
vitro. both TGF-a and IFG-I promoted cell growth and the
mitogenic responses were additive. suggesting an independent
effect at different receptors (Durrant et al.. 1991). In addi-
tion. both growth factors enhanced the response of these cells
to gastrin. This suggests that the prevention of binding and
or secretion of these factors in conjunction with gastrin may
have therapeutic potential in gastrointestinal tumours.
Specific receptors for bombesin gastrin-releasing peptide
and somatostatin have recently been identified in human
colon cancers (Radulovic et al.. 1992). By using specific
antagonists to the gastrin cholecystokinin and somatostatin
receptors the gastrin-stimulated growth of gastrointestinal
tumour cells in vitro can be inhibted (Watson et al., 1992).
Furthermore. alterations to gastrin secretion using the
bombesin gastrin-releasing peptide antagonist RC-3095 or
the somatostatin analogue RC-160 inhibit the growth of
MKN45 human gastric carcinoma xenografts in nude mice
(Pinski et al.. 1994). It is paradoxical that another group of
drugs which cause hypergastrinaemia secondary to their
reduction in gastric acid output also have a putative anti-
cancer role in gastrointestinal malignancy.
Cimetidine. a histamine-2 receptor antagonist. can reverse
the histamine-stimulated growth of gastric cancer cells both
in *itro and in vivo (Watson et al.. 1993). Cimetidine also
inhibits cellular proliferation and slows early tumour
invasion in an animal model of carcinogen-induced colon
cancer compatible with a role independent of a host cellular
immune response (Adams et al.. 1993). These experimental
data are strongly supported by a double-blind randomised
trial of 181 patients with operated or inoperable gastric
cancer which reported a median surVival of 450 days in the
cimetidine-treated arm compared with 316 days in the
placebo arm (Tonneson et al.. 1988). The anti-tumour effect
of cimetidine has been attributed to several putative
immunomodulatory actions. including suppressor T-cell
inhibition, increased interleukin 2 in helper T cells as well as
enhanced natural killer cell activity. The results of several
other clinical trials using this group of drugs are awaited.
Until recently little has been known about the interaction
of dietary factors and the epithelial cells of the gastrointes-
tinal tract. Recent studies, however, have identified increased
expression of the Thomsen-Friedenreich (TF) antigen in
hyperplastic and malignant epithelium, which includes a
specific Gal-beta-1.3-Gal NAc binding area. Dietary lectins
such as the protein peanut agglutinin (PNA), which are
known to bind to the TF antigen. are mitogenic for colon
cancer cells in vitro (Ryder et al.. 1992). In contrast, dietary
lectins may also have an antiproliferative effect by binding to
the TF antigen. One such example is the Agaricus bisporus
(edible mushroom) lectin, which can cause reversible inhibi-
tion of proliferation of colon and breast cancer cell lines in
vitro (Yu et al., 1993). This agent and other protective lectins
merit further study as potential anti-cancer agents. and this
may establish a way for dietary modification to influence the
prevention of gastrointestinal cancer.
In conclusion, there are now several alternative treatment
strategies which may be of benefit in the treatment of gast-
rointestinal cancers. Although there is much experimental
evidence from both in vitro and in vivo studies to support
these potential treatment options. further clinical trials are
essential to establish the exact role of hormonal growth fac-
tor manipulation. histamine-2 receptor antagonists and
dietary modification in the prevention and treatment of these
tumours. but the evidence to date is extremely encouraging.
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